ecancermedicalscience

Case Report

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib

30 May 2022
Shubham Tomar, Lakhan Kashyap, Akhil Kapoor

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted therapy with fewer adverse effects. Here we present a case of a 42-year-old female having isolated renal cell carcinoma, papillary type 2, carrying a mutation in the FH gene without cutaneous and uterine involvement. Her tumour responded well to erlotinib and bevacizumab combination and she was on treatment for 23 months. This report adds to the current literature and can help to define treatment protocols for HLRCC.

Related Articles

Shreekant Dadheech, Kaustubh Burde, Pariseema Dave, Ruchi Arora, Chetna Parekh
Kamboji Sharanya, Lulu Abdul khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma
Mehak Trikha, Vanita Noronha, Minit Shah, Vijay Patil, Nandini Menon, Ajaykumar Singh, Pratik Chandrani, Omshree Shetty, Rajiv Kumar Kaushal, Trupti Pai, Amit Janu, Nilendu Purandare, Kumar Prabhash
Talita Alves do Nascimento Santos, Anna Karoline Fausto da Silva, Karin Soares Gonçalves Cunha, Camila Braz Pereira da Costa, Aldo Rodrigues da Silva, Helena Carla Castro, Nathália Silva Carlos Oliveira
Ramila Shilpakar, KC Anuj, Bibek Acharya, Sandhya Chapagain, Shama Pandey, Prakash Neupane, Bishal Poudel, Soniya Dulal, Bishnu Dutta D Poudel